Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis

NCT04999020 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

38

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

Dermatomyositis

Interventions

DRUG: Ravulizumab
DRUG: Placebo

Sponsor

Alexion Pharmaceuticals, Inc.